Overview
Vanishing bile duct syndrome (VBDS) is a severe adverse reaction characterized by progressive destruction of intrahepatic bile ducts, often triggered by nonsteroidal anti-inflammatory drugs (NSAIDs), leading to liver dysfunction and potentially fatal outcomes 1.Diagnosis
Key Symptoms: Rash, jaundice, fatigue/asthenia, Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) 1.
Laboratory Findings: Elevated total bilirubin (TBIL), abnormal liver function tests 1.
Onset Timing: Typically within 4 weeks of NSAID exposure 1.
Imaging: May show cholestasis or biliary abnormalities, though specific imaging criteria are not detailed in the abstracts 1.Management
Discontinue NSAIDs: Immediate cessation of the offending NSAID 1.
Supportive Care: Management of symptoms including hydration, nutritional support, and monitoring for complications like sepsis 1.
Liver Support: Consideration of liver transplantation in severe cases with irreversible liver failure 1.
Specific Treatments: No specific pharmacological treatments beyond supportive care are highlighted in the abstracts 1.Special Populations
Pediatrics: Represents a notable subset with 37.5% of cases reported in children 1.
Prognosis: Poor overall prognosis with significant mortality noted, particularly in pediatric cases 1.Key Recommendations
Avoid NSAIDs in High-Risk Patients: Particularly in those with a history of skin reactions or liver disease to prevent VBDS (Evidence: Moderate) 1.
Prompt Recognition and NSAID Withdrawal: Early identification and discontinuation of NSAIDs is crucial to mitigate progression (Evidence: Moderate) 1.
Close Monitoring of Liver Function: Regular monitoring of liver function tests in patients on NSAIDs, especially after initiation, to detect early signs of VBDS (Evidence: Weak) 1.References
1 Wang J, Wu C, Deng Z. Nonsteroidal anti-inflammatory drugs-associated vanishing bile duct syndrome: a real-world retrospective and disproportionality analysis. Expert opinion on drug safety 2026. link